Abstract:Divya Ail, Hugo Malki, Emilia A Zin, Deniz Dalkara Sorbonne Université, INSERM, CNRS, Department of Therapeutics, Institut de la Vision, Paris, 75012, France Correspondence: Divya Ail, Department of Therapeutics, Institut de la Vision, 17 Rue Moreau, Paris, 75012, France, Tel +33 153462648, Email Owing to their small size and safety profiles, adeno-associated viruses (AAVs) have become the vector of choice for gene therapy applications in the retina. In addition to the naturally occurring AAVs, several engineered variants with enhanced properties are being developed for experimental and therapeutic applications. Nonetheless, there are still some challenges impeding successful application of AAVs for a broader range of retinal gene therapies. The small size of AAV particles ensures efficient tissue transduction but also limits the packaging capacity to a few kilobases. Further, AAV's ability to cross retinal barriers is still an obstacle to pan-retinal transduction of the outer retina with tolerable doses. Lastly, despite overall safety, there have been recent reports of immune responses to AAVs in the eye. Hence, evaluation and prediction of immune responses to AAVs has come to be considered an integral part of future clinical success. This review focuses on the use of AAV in clinical trials for retinal diseases, and discusses developments of variants and novel strategies to overcome immune responses to AAVs. Keywords: retinal gene therapy, adeno-associated virus, AAV, clinical trials, capsid variants, immune responses AAVs are non-pathogenic viruses belonging to the Parvoviridae family under the genus Dependoparvovirus . They can infect humans but are non-pathogenic and are known to have low immunogenicity. They are naturally replication-deficient and hence termed as 'helper-dependent virus' as they depend on the presence of adenovirus, herpesvirus or papilloma virus as helpers to replicate. 1–3 In the absence of a 'helper virus' AAV remains latent by integrating into the host genome or remaining as extrachromosomal episomes. AAVs are small, non-enveloped viruses with a capsid size of 25nm and package single-stranded DNA of approximately 4700 base pairs. 4 There are 13 naturally occurring AAV serotypes (AAV1 – AAV13) and 100s of AAV variants have been identified or engineered. These AAV serotypes possess distinct tropisms that are tissue specific and species specific. The tissue tropism/specificity of AAVs is determined by the proteins on the surface of capsids. The capsid proteins bind specific cell-surface receptors which in turn recruit co-receptors leading to internalization by endocytosis into the cell. 5 Following internalization AAVs escape the endosomes and gain entry into the nucleus. 6 AAV relies on the host cell mechanisms for the second strand synthesis. 7 For experimental and clinical applications recombinant AAVs (rAAV) are created by replacing the viral genome by the transgene of interest while retaining the ITRs. The ITRs flank the transgene and ensure its encapsidation within the AAV. The other structural (capsid proteins) and non-structural (replication and helper) genes are supplied separately. 4,8 rAAVs rarely integrate into the host cell genome, thereby reducing the risk of insertional mutagenesis following gene therapy. Gene therapy refers to the introduction of genetic material into tissues to rectify the effects of disease-causing mutations. Inherited diseases caused by gene mutations resulting in deficiency or malfunction of proteins involved in cellular functions are ideal targets for gene therapy. Such diseases can be treated by replacement of the entire defective gene, silencing of the mutation or correction/editing of the mutation. The therapeutic gene is packaged into AAVs and delivered to target tissue by local injections. 9 AAV delivery to the retina is normally done by two routes: subretinal and intravitreal. Subretinal injection (SRI) involves injection between the Retinal Pigment Epithelium (RPE) and the photoreceptors resulting in efficient AAV delivery to the outer retina. Intravitreal injection (IVT) involves AAV delivery into the vitreous space thereby causing transduction of the Ganglion Cell Layer (GCL) and some other cell types of the inner retina. 10 The retina is an ideal target for gene therapy due to two main reasons: First, many gene mutations responsible for Inherited Retinal Diseases (IRDs) have been identified, 11 and second, the retina is enclosed within the eye in a relatively immune-privileged space. The retina is shielded by a blood-retinal barrier and also benefits from the unique intraocular microenvironment. 12 This prevents the occurrence of a strong systemic effect to the AAV-mediated ocular gene therapy. Over the last five -Abstract Truncated-

AAV for Gene Therapy in Ocular Diseases: Progress and Prospects

Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy

Adeno-associated virus as a delivery vector for gene therapy of human diseases

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges

AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies

AAV-mediated gene therapy: Advancing cardiovascular disease treatment

AAV-Based Targeting Gene Therapy

Insights into Adeno-Associated Virus-Based Ocular Gene Therapy: A Bibliometric and Visual Analysis

Engineering adeno-associated virus vectors for gene therapy

AAV-based in vivo gene therapy for neurological disorders

AAV-mediated gene therapies for glaucoma and uveitis: are we there yet?

Adeno-associated virus vector as a platform for gene therapy delivery

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

Lentiviral Vectors for Ocular Gene Therapy